Prevention of acute thrombosis with vascular endothelium antioxidative nanoscavenger

Area of Science:

• Biomedical Engineering
• Vascular Biology
• Nanomedicine

Background:

• Antiplatelet drugs are crucial for thrombosis treatment but have limitations including bleeding risk and efficacy.
• Excessive reactive oxygen species (ROS) from damaged endothelial cells contribute to thrombosis.
• Current therapies do not adequately address the dual challenge of efficacy and safety in antithrombotic treatment.

Purpose of the Study:

• To investigate a novel ROS-chemotactic nanoscavenger (MDCP) as a potential antithrombotic strategy.
• To evaluate MDCP's ability to protect vascular endothelial cells from oxidative stress and prevent thrombosis.
• To assess MDCP's safety profile by examining its impact on bleeding risk.

Main Methods:

• MDCP was synthesized by crosslinking melanin and catalase.
• The efficacy of MDCP in preventing ROS-induced endothelial cell apoptosis was assessed.
• The effect of MDCP on platelet activation and thrombosis formation was evaluated in vitro and in vivo.
• The impact of MDCP on bleeding risk was compared to conventional antiplatelet drugs.

Main Results:

• MDCP treatment inhibited ROS-induced apoptosis of endothelial cells, preserving endothelial integrity.
• MDCP prevented collagen exposure on damaged endothelial cells, a key trigger for platelet activation.
• MDCP effectively prevented platelet activation and acute thrombosis formation.
• MDCP demonstrated a reduced bleeding risk compared to existing antithrombotic agents.

Conclusions:

• MDCP represents a novel nanoscavenger therapy that prevents thrombosis by targeting vascular oxidative stress.
• By maintaining endothelial integrity and avoiding direct platelet interference, MDCP offers a promising antithrombotic strategy with a potentially improved safety profile.
• This approach modulates vascular redox homeostasis, addressing the limitations of current antiplatelet drugs and offering a new avenue for thrombosis management.